Evidence map›Paper›PMID 42163716›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Simon Nannini, Céline Sieffert, Andrew McGown, Xin-Yue Gao, Amanda Jarvis, Georges E Kostakis, Antal Galvacsi, Csilla Kallay, Ruxandra Moraru, Matthias G Baud and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Simon Nannini"Streinth" Laboratory, University of Strasbourg, INSERM UMR_S 1113, Strasbourg, France.
Céline Sieffert"SMART" Laboratory, University of Strasbourg, INSERM UMR_S 1113, Strasbourg, France.
Andrew McGownSussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Brighton, East Sussex, UK.
Xin-Yue GaoEastCHEM School of Chemistry, University of Edinburgh, Joseph Black Building, Edinburgh, UK.
Amanda JarvisEastCHEM School of Chemistry, University of Edinburgh, Joseph Black Building, Edinburgh, UK.
Georges E KostakisDepartment of Chemistry, School of Life Sciences, University of Sussex, Brighton, East Sussex, UK.
Antal GalvacsiDepartment of Inorganic and Analytical Chemistry, University of Debrecen, Debrecen, Hungary.
Csilla KallayDepartment of Inorganic and Analytical Chemistry, University of Debrecen, Debrecen, Hungary.
Ruxandra MoraruSchool of Chemistry, University of Southampton, Southampton, UK.
Matthias G BaudSchool of Chemistry, University of Southampton, Southampton, UK.
Sebastian MandelInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.
Dimitros-Ilias BalourdasInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.
Andreas C JoergerInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.
Christophe Orvain"Streinth" Laboratory, University of Strasbourg, INSERM UMR_S 1113, Strasbourg, France.
Simon Peschard"HERIT" Laboratory, University of Strasbourg, INSERM UMR 1260, Strasbourg, France.
Audrey Nion"HERIT" Laboratory, University of Strasbourg, INSERM UMR 1260, Strasbourg, France.
Georg Mellitzer"Streinth" Laboratory, University of Strasbourg, INSERM UMR_S 1113, Strasbourg, France.
Sophie Lottiaux"Streinth" Laboratory, University of Strasbourg, INSERM UMR_S 1113, Strasbourg, France.
John SpencerSussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Brighton, East Sussex, UK.
Isabelle Gross"SMART" Laboratory, University of Strasbourg, INSERM UMR_S 1113, Strasbourg, France.
Christian Gaiddon"Streinth" Laboratory, University of Strasbourg, INSERM UMR_S 1113, Strasbourg, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Point mutations in p53 favour tumour aggressivity, particularly in gastric cancer (GC), and offer a target for small molecule-based anticancer treatments. This study focused on the p53-Y220C mutation, which causes p53 misfolding due to thermal instability associated with the creation of a pocket that may accommodate small molecules. This mutation also creates an additional free cysteine thiol group that may react with Michael acceptors. Using an integrated

Indexed as

Antineoplastic AgentsChelating AgentsCyclin-Dependent Kinase Inhibitor p21Stomach NeoplasmsTumor Suppressor Protein p53ZincCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorHumansMolecular StructureMutationStructure-Activity RelationshipAntineoplastic AgentsChelating AgentsCyclin-Dependent Kinase Inhibitor p21TP53 protein, humanTumor Suppressor Protein p53Zinccovalent drugsgastric cancermetal chelationp53targeted therapy

Identifiers

PMID42163716
PMCPMC13195717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.